|Mr. Andrew David William Newland||Founder, CEO & Exec. Director||531.35k||N/A||1962|
|Mr. Ian Francis Griffiths||CFO, Fin. Director, Company Sec. & Exec. Director||340.23k||N/A||1965|
|Mr. Andrew John Holder||Head of Investor Relations||N/A||N/A||N/A|
|Dr. Madeline Repollet||Head of Clinical Laboratories||N/A||N/A||N/A|
|Ms. Anne-Sophie Pailhes-Jimenez||Head of R&D - ANGLE Europe Ltd.||N/A||N/A||N/A|
|Dr. Todd Druley||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Paul Smith||VP & Chief Exec. Officer of ANGLE Biosciences Inc||N/A||N/A||N/A|
|Mr. Martin Cooke||Director of Manufacturing & Regulatory Affairs||N/A||N/A||1969|
|Mr. Michael O'Brien||Bus. Devel. Director||N/A||N/A||N/A|
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products worldwide. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and HyCEAD multiplex analysis system used as the downstream analysis tool in the ovarian cancer clinical application. It also offers specialist circulating tumor cell enrichment and analysis services to support translational research studies and pharmaceutical trials. The company was founded in 1994 and is based in Guildford, the United Kingdom.
ANGLE plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.